Nafamostat (mesylate) (Standard)

Nafamostat (mesylate) (Standard) is the analytical standard of Nafamostat (mesylate) . This product is intended for research and analytical applications. Nafamostat mesylate (FUT-175), an anticoagulant, is a synthetic serine protease inhibitor. Nafamostat mesylate has anticancer and antivirus effect. Nafamostat mesylate induce apoptosis by up-regulating the expression of tumor necrosis factor receptor-1 (TNFR1) . Nafamostat mesylate can be used in the development of the pathological thickening of the arterial wall[1][2][3][4].

Product Specifications

CAS Number

[82956-11-4]

UNSPSC

12352100

Target

Apoptosis; Flavivirus; NF-κB; Reference Standards; Ser/Thr Protease; TNF Receptor

Related Pathways

Anti-infection; Apoptosis; Metabolic Enzyme/Protease; NF-κB; Others

Field of Research

Cancer; Infection

Smiles

CS(=O)(O)=O.O=C(OC1=CC=C2C=C(C(N)=N)C=CC2=C1)C3=CC=C(NC(N)=N)C=C3.CS(=O)(O)=O

Molecular Formula

C21H25N5O8S2

Molecular Weight

539.58

References & Citations

[1]Uwagawa T, et al. Mechanisms of synthetic serine protease inhibitor (FUT‐175) ‐mediated cell death [J]. Cancer: Interdisciplinary International Journal of the American Cancer Society, 2007, 109 (10) : 2142-2153.|[2]Tajima H, et al. Enhanced invasiveness of pancreatic adenocarcinoma cells stably transfected with cationic trypsinogen cDNA [J]. International journal of cancer, 2001, 94 (5) : 699-704.|[3]Yan Y, et al. Nafamostat mesylate as a broad-spectrum candidate for the treatment of flavivirus infections by targeting envelope proteins [J]. Antiviral research, 2022, 202: 105325.|[4]Sawada M, et al. Prevention of neointimal formation by a serine protease inhibitor, FUT-175, after carotid balloon injury in rats [J]. Stroke, 1999, 30 (3) : 644-650.